AVITA Medical Inc (ASX:AVH) Shares Reach 52-Week High at AUD 2.30

Anjali Anand

12 August 2026 07:27 PM AEST

AVITA Medical Inc (ASX:AVH) Shares Reach 52-Week High at AUD 2.30

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

AVITA Medical Inc (ASX:AVH) shares reached a 52-week high of AUD 2.30 on 12 August 2026.
The stock closed at AUD 2.28 after increasing 7.04% during the session.
Shares traded between AUD 2.20 and AUD 2.30 during the trading day.
The company’s Market Capitalisation was approximately AUD 381.9mn based on the provided data.
AVITA Medical’s latest share price moved close to the highest level recorded over the past year.

AVITA Medical Inc (ASX:AVH) recorded a new 52-week high on 12 August 2026, with its shares reaching AUD 2.30 during the trading session. The stock closed at AUD 2.28, representing a daily increase of 7.04% or AUD 0.15 compared with the previous close of AUD 2.13.

The company’s shares opened at AUD 2.28 and traded between a low of AUD 2.20 and a high of AUD 2.30 during the session. The closing price remained close to the highest level recorded during the day.

The latest movement placed AVITA Medical among ASX-listed healthcare stocks trading near their highest levels recorded over the previous 12 months.

ASX:AVH Share Price Movement on 12 August 2026

During the session, AVITA Medical shares moved above the previous closing price of AUD 2.13. The stock gained AUD 0.15 and ended the day at AUD 2.28, which was AUD 0.02 below the intraday high of AUD 2.30.

The provided market data showed AVITA Medical’s market capitalisation at 38.19Cr, which converts to approximately AUD 381.9mn. The company’s 52-week trading range was listed between AUD 1.00 and AUD 2.30.

The available data did not include Dividend information, with quarterly dividend details also unavailable.

Understanding AVITA Medical’s 52-Week High Level

A 52-week high represents the highest price level reached by a company’s shares over the previous 12 months. For AVITA Medical Inc, the recorded 52-week high was AUD 2.30, while the 52-week low was AUD 1.00.

The closing price of AUD 2.28 placed the stock near the upper end of its annual trading range. This provides a reference point for comparing the latest share price with levels recorded over the previous year.

However, a 52-week high only reflects historical market performance. It does not explain the reasons behind the share price movement or indicate future price performance. Additional company disclosures would be required for a broader assessment.

AVITA Medical Trading Details and Market Data

The 12 August 2026 session showed AVITA Medical shares opening at AUD 2.28 before moving to a high of AUD 2.30. The stock also recorded AUD 2.20 as the session low.

The share price increase of AUD 0.15 compared with the previous close resulted in the stock ending close to its highest daily level. The difference between the 52-week low of AUD 1.00 and the latest high of AUD 2.30 shows the range within which the shares traded over the previous year.

The available market data focused on share price performance, market capitalisation, and annual trading range.

52-Week High ASX Healthcare Stocks and Market Activity

Healthcare stocks reaching 52-week highs are often monitored as they represent companies trading at their highest levels within a recent one-year period. These milestones provide information about market activity but do not independently explain the factors influencing share price movements.

For AVITA Medical Inc, the latest session showed the stock moving from AUD 2.20 at the daily low to AUD 2.30 at the high, with the closing price remaining close to the top of the trading range.

The available information confirms the latest market performance of AVITA Medical but does not include additional operational updates, financial results, or company announcements.

AVITA Medical’s Latest Share Price Position

AVITA Medical’s latest Trading session placed the stock near the upper end of its 52-week range. The company’s shares traded between AUD 1.00 and AUD 2.30 over the previous 12 months based on the provided data.

The closing price of AUD 2.28 was close to the company’s 52-week high of AUD 2.30, reflecting the latest position of the share price within its annual range.

For readers following ASX stocks reaching 52-week highs, this movement provides a snapshot of market activity, while additional company information would be required to assess other factors.

Conclusion

AVITA Medical Inc (ASX:AVH) reached a 52-week high of AUD 2.30 on 12 August 2026 before closing at AUD 2.28. The shares increased by 7.04%, or AUD 0.15, compared with the previous close of AUD 2.13. The stock traded between AUD 2.20 and AUD 2.30 during the session, while the market capitalisation was approximately AUD 381.9mn based on the provided data. The latest session placed AVITA Medical near the upper end of its annual trading range, with the available information focused on market performance only.

FAQs

Q: What was AVITA Medical Inc’s (ASX:AVH) closing share price on 12 August 2026?

A:AVITA Medical Inc closed at AUD 2.28 on 12 August 2026.

Q: What was AVITA Medical Inc’s 52-week high price?

A:The company’s recorded 52-week high was AUD 2.30.

Q: How much did AVITA Medical shares rise during the session?

A:The shares increased by 7.04%, or AUD 0.15, compared with the previous close of AUD 2.13.

Q: What was AVITA Medical’s trading range on 12 August 2026?

A:The stock traded between AUD 2.20 and AUD 2.30 during the session.

Q: What was AVITA Medical’s market capitalisation?

A:Based on the provided data, AVITA Medical’s market capitalisation was approximately AUD 381.9mn.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.